CINECA IRIS Institutional Research Information System

ROSSINI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.630
AS - Asia 1.432
EU - Europa 1.124
SA - Sud America 294
AF - Africa 81
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.564
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.574
SG - Singapore 497
IT - Italia 383
CN - Cina 368
HK - Hong Kong 303
BR - Brasile 245
DE - Germania 178
SE - Svezia 114
GB - Regno Unito 109
VN - Vietnam 96
BG - Bulgaria 81
FR - Francia 76
FI - Finlandia 46
RU - Federazione Russa 42
CI - Costa d'Avorio 38
CA - Canada 36
IN - India 32
JP - Giappone 27
AR - Argentina 23
TR - Turchia 23
PL - Polonia 21
MX - Messico 16
NL - Olanda 16
BD - Bangladesh 13
NG - Nigeria 13
ID - Indonesia 12
IQ - Iraq 11
ES - Italia 10
UA - Ucraina 9
KR - Corea 8
CZ - Repubblica Ceca 7
SN - Senegal 7
AT - Austria 6
LT - Lituania 6
SA - Arabia Saudita 6
CO - Colombia 5
IE - Irlanda 5
CL - Cile 4
EC - Ecuador 4
EG - Egitto 4
MY - Malesia 4
PH - Filippine 4
UY - Uruguay 4
ZA - Sudafrica 4
KH - Cambogia 3
MA - Marocco 3
PE - Perù 3
PK - Pakistan 3
PT - Portogallo 3
PY - Paraguay 3
UZ - Uzbekistan 3
VE - Venezuela 3
AO - Angola 2
AZ - Azerbaigian 2
BB - Barbados 2
DZ - Algeria 2
KE - Kenya 2
KG - Kirghizistan 2
LV - Lettonia 2
PS - Palestinian Territory 2
RO - Romania 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AU - Australia 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CH - Svizzera 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EU - Europa 1
HR - Croazia 1
IL - Israele 1
IM - Isola di Man 1
IR - Iran 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LY - Libia 1
MD - Moldavia 1
MT - Malta 1
NA - Namibia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 5.564
Salva come PNG Salva come JPEG
Città #
Ashburn 298
Hong Kong 298
Santa Clara 262
Singapore 259
Fairfield 221
Dallas 208
Woodbridge 202
Chandler 126
Houston 121
Shanghai 105
Seattle 104
Wilmington 95
Cambridge 85
Sofia 81
New York 79
Ann Arbor 72
Beijing 68
Boardman 64
Florence 60
Los Angeles 54
Munich 54
London 47
Pisa 43
Abidjan 38
Princeton 37
Lawrence 36
Ho Chi Minh City 30
Milan 28
Cascina 27
Medford 25
Ottawa 24
Serra 23
São Paulo 22
Tokyo 22
Redondo Beach 21
Turku 21
Rome 20
Dearborn 19
Frankfurt am Main 19
Bremen 18
Seacroft 18
Turin 18
Warsaw 18
Hefei 17
Ogden 17
Des Moines 16
Helsinki 15
Istanbul 14
Buffalo 13
Genoa 13
Lagos 13
Lancaster 13
Düsseldorf 12
Nanjing 12
Fuzhou 11
Orem 11
San Diego 10
Verona 10
Hanoi 9
Dong Ket 8
Kent 8
Rio de Janeiro 8
Seoul 8
Atlanta 7
Boulder 7
Dakar 7
Denver 7
Fortaleza 7
Kunming 7
Paris 7
Phoenix 7
Quanzhou 7
Redwood City 7
Baghdad 6
Chicago 6
Montreal 6
Porto Alegre 6
Brooklyn 5
Chennai 5
Positano 5
Amsterdam 4
Ankara 4
Avaré 4
Boston 4
Da Nang 4
Dublin 4
Guangzhou 4
Guarulhos 4
Hebei 4
Hyderabad 4
Jinan 4
Lauterbourg 4
Montevideo 4
Mumbai 4
Nanchang 4
Nuremberg 4
Olomouc 4
Osasco 4
Polverigi 4
Poplar 4
Totale 3.917
Salva come PNG Salva come JPEG
Nome #
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 193
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 172
TAS-102 for the treatment of metastatic colorectal cancer 171
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 159
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 158
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 154
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 146
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 144
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 141
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 141
A still missing piece of the FIRE-3 puzzle 139
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 138
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer 137
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 137
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients 136
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 135
Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram 135
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 135
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 134
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 129
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 121
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 118
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 111
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 109
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 109
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 104
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 102
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study 100
null 98
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study 98
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 97
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 91
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 90
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 89
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 88
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib 86
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 85
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 83
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 83
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 80
Individual patient data meta-analysis of folfoxiri plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer 79
Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy 70
null 69
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 68
Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence 67
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer 63
TRIBE2 results and toxicity – Authors' reply 63
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 60
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study 59
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 53
TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply 47
KDR genetic predictor of toxicities induced by sorafenib and regorafenib 44
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis 42
Merkel cell carcinoma of the retroperitoneum with no identifiable primary site 25
Evaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC 17
Totale 5.702
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.697
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.697
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021286 0 0 0 0 0 81 32 19 55 17 24 58
2021/2022317 4 4 7 5 58 56 4 10 18 37 24 90
2022/2023528 51 75 38 36 46 51 28 30 92 2 70 9
2023/2024424 18 36 59 34 60 59 27 16 9 14 48 44
2024/20251.732 34 64 39 80 179 230 128 92 162 186 192 346
2025/20261.265 157 239 259 228 252 130 0 0 0 0 0 0
Totale 5.702